Letters to the Editor
Early Access
https://doi.org/10.4081/monaldi.2026.3718

Eczema-like cutaneous lesions in idiopathic pulmonary fibrosis: a shared Th2-driven pathway?

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 7 September 2025
Published: 9 July 2026
206
Views
84
Downloads
Idiopathic pulmonary fibrosis, Th2 inflammation, atopic eczema, cytokines, immune dysregulation

Authors

Aldo Pezzuto
Unit of Pulmonology, Department of Cardiovascular and Respiratory Sciences, Sant’Andrea Hospital, Sapienza University, Rome, Italy.
Ilaria Demofonte
Unit of Dermatology of Dermatology, Department of Medical and Cardiovascular Science, Sapienza Medical School of Rome, Italy.
Francesca Romana Parisella
Department of Medicine, University of Queensland, Brisbane, Australia.
Fabiola Luzi
Plastic and Reconstructive Surgery, San Gallicano Dermatologic Institute IRCCS, Rome, Italy.
Gabriella De Marco
Department of Dermatology, Sant’Andrea General Hospital, Sapienza University of Rome, Italy.
Antonella Tammaro
tammaroantonella@gmail.com
Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.

Dear Editor,
Idiopathic pulmonary fibrosis is the most frequent form of idiopathic interstitial pneumonia, characterized by a progressive course and poor prognosis, with a median survival of 3-5 years after diagnosis...

Downloads

Download data is not yet available.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018;198:e44-68. DOI: https://doi.org/10.1164/rccm.201807-1255ST

Harari S, Caminati A. Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. Eur Respir Rev 2015;24:420-7. DOI: https://doi.org/10.1183/16000617.0042-2015

Singh P, Guin D, Pattnaik B, Kukreti R. Mapping the genetic architecture of idiopathic pulmonary fibrosis: Meta-analysis and epidemiological evidence of case-control studies. Gene 2024;895:147993. Erratum in: Gene 2025;941:149223. DOI: https://doi.org/10.1016/j.gene.2025.149223

Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biol 2018;68-69:404-21. DOI: https://doi.org/10.1016/j.matbio.2018.01.023

Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int J Mol Sci 2021;22:6211. DOI: https://doi.org/10.3390/ijms22126211

Mandlik DS, Mandlik SK. Atopic dermatitis: new insight into the etiology, pathogenesis, diagnosis and novel treatment strategies. Immunopharmacol Immunotoxicol 2021;43:105-25. DOI: https://doi.org/10.1080/08923973.2021.1889583

Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. DOI: https://doi.org/10.1093/eurheartj/ehv317

Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62:D42-50. DOI: https://doi.org/10.1016/j.jacc.2013.10.032

McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619.

Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018;360:j5492. DOI: https://doi.org/10.1136/bmj.j5492

Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21:321-7. DOI: https://doi.org/10.1183/09059180.00004812

Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol 2021;17:835-52. DOI: https://doi.org/10.1080/1744666X.2021.1940962

Provenzani A, Leonardi Vinci D, Alaimo M, et al. Real-world insights into safety, tolerability, and predictive factors of adverse drug reactions in treating idiopathic pulmonary fibrosis with pirfenidone and nintedanib. Ther Adv Drug Saf 2025;16:20420986251341645. DOI: https://doi.org/10.1177/20420986251341645

Ethics Approval

The study was conducted in accordance with institutional guidelines and approved by the Ethics Committee of Sant’Andrea Hospital, Sapienza University of Rome, Italy (Ethics Committee consent form 273).

How to Cite



“Eczema-Like Cutaneous Lesions in Idiopathic Pulmonary Fibrosis: A Shared Th2-Driven Pathway?”. 2026. Monaldi Archives for Chest Disease, July. https://doi.org/10.4081/monaldi.2026.3718.
Copyright (c) 2026 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.